Generate Biomedicines (NASDAQ:GENB) Shares Down 6.7% – What’s Next?

Generate Biomedicines Inc (NASDAQ:GENB)’s share price dropped 6.7% on Thursday. The company traded as low as $14.11 and last traded at $14.01. 725,887 shares traded hands during trading, a decline of 13% from the average daily volume of 834,337 shares. The stock had previously closed at $15.02.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Generate Biomedicines in a report on Tuesday, September 8th. Wall Street Zen upgraded shares of Generate Biomedicines from a “sell” rating to a “hold” rating in a report on Saturday, September 26th. Finally, Weiss Ratings upgraded shares of Generate Biomedicines from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 25th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.40.

Generate Biomedicines Stock Down 6.7%

The company has a market capitalization of $1.80 billion and a PE ratio of -8.83. The business has a 50 day simple moving average of $15.53 and a 200 day simple moving average of $14.34.

Generate Biomedicines (NASDAQ:GENB) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The firm had revenue of $6.31 million for the quarter. Equities analysts expect that Generate Biomedicines Inc will post -2.29 EPS for the current fiscal year.

Institutional Trading of Generate Biomedicines

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GENB. Braidwell LP purchased a new position in shares of Generate Biomedicines in the second quarter worth about $55,398,000. Squarepoint Ops LLC purchased a new stake in shares of Generate Biomedicines in the 2nd quarter valued at $530,000. State Street Corp purchased a new position in shares of Generate Biomedicines during the second quarter worth $8,883,000. The Manufacturers Life Insurance Company acquired a new position in Generate Biomedicines during the second quarter valued at $1,431,000. Finally, Bank of New York Mellon Corp purchased a new stake in Generate Biomedicines in the second quarter valued at $967,000.

Generate Biomedicines Company Profile

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and machine learning to discover and design protein-based medicines. Its technology is intended to model relationships among protein sequences, structures and biological functions, helping researchers create therapeutic proteins with desired characteristics.

The company’s research activities are focused on developing novel biologic medicines for areas of significant unmet medical need, including oncology, immunology, infectious diseases and rare diseases.